Anti Virus Trial ((free)) ✅

But the trial also revealed a serious flaw. In two patients with pre-existing kidney disease, the drug accumulated to toxic levels, causing acute renal failure. Both recovered after dialysis, but the data were clear: AVI-7 could not be given without prior kidney function screening. The drug’s label would need a bolded warning.

This phase involved 3,500 participants across seven countries—Vietnam, Brazil, Kenya, Finland, India, South Africa, and Canada. The trial was randomized and placebo-controlled, but this time, patients came in with early flu symptoms. The endpoint: did AVI-7 shorten illness and prevent hospitalization? anti virus trial

The results, when unblinded, stunned the medical community. Among high-risk patients (elderly, asthmatics, pregnant women), AVI-7 reduced hospitalization rates by 76 percent compared to placebo. Even more remarkable, viral sequencing showed zero resistance mutations after 60 days of treatment—something never seen with oseltamivir (Tamiflu). But the trial also revealed a serious flaw

Dr. Márquez often told her students: “A trial isn’t a success because the drug works. It’s a success because we honestly learn what it can and cannot do—and we tell the truth about both.” The drug’s label would need a bolded warning

The trial that followed was a masterclass in scientific caution and ethics.

With regulatory approval, 40 healthy volunteers received ascending doses of AVI-7 at a hospital in Oslo. The goal: find side effects. Most reported mild nausea. Two developed temporary liver enzyme elevations, setting a maximum safe dose. No one died. No one got sick from the virus because they were never exposed to it.